| Home | Organizers | Proceedings Editors | Proceedings Contributors | Search | | ||
|
|
|||
|
||||
|
|
||||
| Title: | EFFICACY OF NIFEKALANT HYDROCHLORIDE ON THE MANAGEMENT OF LIFE-THREATENING VENTRICULAR TACHYARRHYTHMIAS IN PATIENTS WITH NON-ISCHEMIC CARDIOMYOPATHY.
This work is supported in part by grants from the Ministry of Health, Labor and Welfare of Japan (to Aizawa Y). |
|
| DOI No: | 10.1142/9789812702234_0089 | |
| Source: | ADVANCES IN ELECTROCARDIOLOGY 2004 (pp 340-343) | |
| Author(s): | TAKASHI WASHIZUKA
Division of Cardiology, Niigata University School of Medical and Dental Sciences, Niigata City, 951-8510, Japan MASAOMI CHINUSHI School of Health Sciences, Faculty of Medicine, Niigata Niigata University, Niigata City, 951-8518, Japan HIROSHI FURUSHIMA Division of Cardiology, Niigata University School of Medical and Dental Sciences, Niigata City, 951-8510, Japan HIROSHI WATANABE Division of Cardiology, Niigata University School of Medical and Dental Sciences, Niigata City, 951-8510, Japan YOSHIFUSA AIZAWA Division of Cardiology, Niigata University School of Medical and Dental Sciences, Niigata City, 951-8510, Japan |
|
| Abstract: | We investigated the effect of nifekalant on VTs with non-ischemic cardiomyopathy. Ten patients with non-ischemic cardiomyopathy and VTs (male 9, female 1, 60±9 yo, LVEF 37±16%) were included in this study. Underlying heart diseases were DCM (n=4), HCM (n=4), ARVC (n=l) and cardiac sarcoidosis (n=l). Nifekalant was administered to suppress the frequent recurrence of VTs. QT and QTc prolonged after nifekalant significantly (p=0.001), respectively. In 6 of 10 patients nifekalant completely suppressed the recurrence of VTs. In other 3 patients, nifekalant decreased the frequency of VTs. In another one, antitachycardia pacing from his ICD could easily terminate VT after nifekalant. Nifekalant was continued for 16±10 days. After nifekalant discontinuation, it was replaced by the combination of amiodarone and ß-blocking agent in 4 patients and by sotalol in 5 patients. Another one patient was treated by catheter ablation. (Conclusion) Nifekalant administration was safe and effective to control recurrent VTs associated with non-ischemic cardiomyopathy. | |
| Full Text: | View full text in PDF format (140KB) | |
| TOC: | Back to Table of Contents | |
|
||